Frovatriptan is effective and well tolerated in Korean migraineurs

A double-blind, randomized, placebo-controlled trial

Heui Soo Moon, Min Kyung Chu, Jeong Wook Park, Kyungmi Oh, Jae Myun Chung, Yong Jin Cho, Eung Gyu Kim, Jin Kuk Do, Hyong Gi Jung, Sun Uck Kwon

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and Purpose Frovatriptan is a selective 5-HT1B/1D agonist with a long duration of action and a low incidence of side effects. Although several placebo-controlled trials have documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has not previously been studied in Asian including Korean patients. Methods In this double-blind multicenter trial, 229 patients with migraine were randomized to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine. The primary outcome was the 2-hour headache response rate. Results Frovatriptan significantly increased the 2-hour headache response rate compared with placebo (52.9% vs. 34.0%, p=0.004). The headache response rates at 4, 6, and 12 hours were significantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2 hours (19.0% vs. 5.7%, p=0.004), 4 hours (40.7% vs. 23.0%, p=0.006), and 6 hours (56.1% vs. 34.0%, p=0.002). The median time to a headache response was significantly shorter in the frovatriptan group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications was more common in the placebo group (p=0.005). Chest tightness associated with triptan was infrequent (2.5%), mild, and transient. Conclusions These results demonstrate that 2.5-mg frovatriptan is effective and well tolerated in Korean migraineurs for acute treatment of migraine attacks.

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalJournal of Clinical Neurology (Korea)
Volume6
Issue number1
Publication statusPublished - 2010 Jan 1

Fingerprint

Randomized Controlled Trials
Placebos
Migraine Disorders
Headache
Tryptamines
Serotonin 5-HT1 Receptor Agonists
frovatriptan
Double-Blind Method
Multicenter Studies
Thorax
Safety
Incidence
Pharmaceutical Preparations

Keywords

  • Frovatriptan
  • Korean
  • Migraine

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Frovatriptan is effective and well tolerated in Korean migraineurs : A double-blind, randomized, placebo-controlled trial. / Moon, Heui Soo; Chu, Min Kyung; Park, Jeong Wook; Oh, Kyungmi; Chung, Jae Myun; Cho, Yong Jin; Kim, Eung Gyu; Do, Jin Kuk; Jung, Hyong Gi; Kwon, Sun Uck.

In: Journal of Clinical Neurology (Korea), Vol. 6, No. 1, 01.01.2010, p. 27-32.

Research output: Contribution to journalArticle

Moon, HS, Chu, MK, Park, JW, Oh, K, Chung, JM, Cho, YJ, Kim, EG, Do, JK, Jung, HG & Kwon, SU 2010, 'Frovatriptan is effective and well tolerated in Korean migraineurs: A double-blind, randomized, placebo-controlled trial', Journal of Clinical Neurology (Korea), vol. 6, no. 1, pp. 27-32.
Moon, Heui Soo ; Chu, Min Kyung ; Park, Jeong Wook ; Oh, Kyungmi ; Chung, Jae Myun ; Cho, Yong Jin ; Kim, Eung Gyu ; Do, Jin Kuk ; Jung, Hyong Gi ; Kwon, Sun Uck. / Frovatriptan is effective and well tolerated in Korean migraineurs : A double-blind, randomized, placebo-controlled trial. In: Journal of Clinical Neurology (Korea). 2010 ; Vol. 6, No. 1. pp. 27-32.
@article{66e70f2aed3c47dea59b5881571c5d67,
title = "Frovatriptan is effective and well tolerated in Korean migraineurs: A double-blind, randomized, placebo-controlled trial",
abstract = "Background and Purpose Frovatriptan is a selective 5-HT1B/1D agonist with a long duration of action and a low incidence of side effects. Although several placebo-controlled trials have documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has not previously been studied in Asian including Korean patients. Methods In this double-blind multicenter trial, 229 patients with migraine were randomized to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine. The primary outcome was the 2-hour headache response rate. Results Frovatriptan significantly increased the 2-hour headache response rate compared with placebo (52.9{\%} vs. 34.0{\%}, p=0.004). The headache response rates at 4, 6, and 12 hours were significantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2 hours (19.0{\%} vs. 5.7{\%}, p=0.004), 4 hours (40.7{\%} vs. 23.0{\%}, p=0.006), and 6 hours (56.1{\%} vs. 34.0{\%}, p=0.002). The median time to a headache response was significantly shorter in the frovatriptan group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications was more common in the placebo group (p=0.005). Chest tightness associated with triptan was infrequent (2.5{\%}), mild, and transient. Conclusions These results demonstrate that 2.5-mg frovatriptan is effective and well tolerated in Korean migraineurs for acute treatment of migraine attacks.",
keywords = "Frovatriptan, Korean, Migraine",
author = "Moon, {Heui Soo} and Chu, {Min Kyung} and Park, {Jeong Wook} and Kyungmi Oh and Chung, {Jae Myun} and Cho, {Yong Jin} and Kim, {Eung Gyu} and Do, {Jin Kuk} and Jung, {Hyong Gi} and Kwon, {Sun Uck}",
year = "2010",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "27--32",
journal = "Journal of Clinical Neurology (Korea)",
issn = "1738-6586",
publisher = "Korean Neurological Association",
number = "1",

}

TY - JOUR

T1 - Frovatriptan is effective and well tolerated in Korean migraineurs

T2 - A double-blind, randomized, placebo-controlled trial

AU - Moon, Heui Soo

AU - Chu, Min Kyung

AU - Park, Jeong Wook

AU - Oh, Kyungmi

AU - Chung, Jae Myun

AU - Cho, Yong Jin

AU - Kim, Eung Gyu

AU - Do, Jin Kuk

AU - Jung, Hyong Gi

AU - Kwon, Sun Uck

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background and Purpose Frovatriptan is a selective 5-HT1B/1D agonist with a long duration of action and a low incidence of side effects. Although several placebo-controlled trials have documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has not previously been studied in Asian including Korean patients. Methods In this double-blind multicenter trial, 229 patients with migraine were randomized to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine. The primary outcome was the 2-hour headache response rate. Results Frovatriptan significantly increased the 2-hour headache response rate compared with placebo (52.9% vs. 34.0%, p=0.004). The headache response rates at 4, 6, and 12 hours were significantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2 hours (19.0% vs. 5.7%, p=0.004), 4 hours (40.7% vs. 23.0%, p=0.006), and 6 hours (56.1% vs. 34.0%, p=0.002). The median time to a headache response was significantly shorter in the frovatriptan group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications was more common in the placebo group (p=0.005). Chest tightness associated with triptan was infrequent (2.5%), mild, and transient. Conclusions These results demonstrate that 2.5-mg frovatriptan is effective and well tolerated in Korean migraineurs for acute treatment of migraine attacks.

AB - Background and Purpose Frovatriptan is a selective 5-HT1B/1D agonist with a long duration of action and a low incidence of side effects. Although several placebo-controlled trials have documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has not previously been studied in Asian including Korean patients. Methods In this double-blind multicenter trial, 229 patients with migraine were randomized to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine. The primary outcome was the 2-hour headache response rate. Results Frovatriptan significantly increased the 2-hour headache response rate compared with placebo (52.9% vs. 34.0%, p=0.004). The headache response rates at 4, 6, and 12 hours were significantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2 hours (19.0% vs. 5.7%, p=0.004), 4 hours (40.7% vs. 23.0%, p=0.006), and 6 hours (56.1% vs. 34.0%, p=0.002). The median time to a headache response was significantly shorter in the frovatriptan group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications was more common in the placebo group (p=0.005). Chest tightness associated with triptan was infrequent (2.5%), mild, and transient. Conclusions These results demonstrate that 2.5-mg frovatriptan is effective and well tolerated in Korean migraineurs for acute treatment of migraine attacks.

KW - Frovatriptan

KW - Korean

KW - Migraine

UR - http://www.scopus.com/inward/record.url?scp=78651488665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651488665&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 27

EP - 32

JO - Journal of Clinical Neurology (Korea)

JF - Journal of Clinical Neurology (Korea)

SN - 1738-6586

IS - 1

ER -